<DOC>
	<DOC>NCT01601470</DOC>
	<brief_summary>This study was conducted to investigate the potential for a pharmacokinetic drug-drug interaction in support of the co-administration of LCZ696 and sildenafil.</brief_summary>
	<brief_title>Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension</brief_title>
	<detailed_description>This study was conducted to investigate the potential for a pharmacokinetic drug-drug interaction in patients with mild-to-moderate hypertension in support of the co-administration of LCZ696 and sildenafil.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Male subjects with mild to moderate hypertension, either treated or not currently on treatment, between age 18 and 65 years of age, and otherwise in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. At screening: systolic blood pressure 120140 mmHg on therapy, or 140160 mmHg if untreated At screening: diastolic blood pressure, 7095 mmHg on therapy, or 90100 mmHg if untreated Baseline: BP â‰¥140/90; Use of nonantihypertensive prescription drugs, herbal supplements, and/or overthecounter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>LCZ696, sildenafil, pharmacokinetics, mild to moderate hypertension</keyword>
</DOC>